Intellia Therapeutics' Gene Editing Technology Looks Promising; FVE $85, Shares Undervalued

We’ve launched coverage of Intellia Therapeutics, a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. We assign Intellia a fair value estimate of $85 per share and view the stock as undervalued, currently trading in 4-star territory. While the company does not yet have approved products, it provides long-term investors with pure play exposure to novel gene editing technology to treat severe, genetic diseases. We assign Intellia a no-moat rating and positive trend. Intellia is developing several pipeline candidates spanning a diverse range of diseases with very high unmet needs, which will likely lead to pricing power if its drugs receive approval.